Orexo to participate in Pareto Securities´ 16th Annual Healthcare Conference 2025

Uppsala, Sweden – September 8, 2025 – Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company will participate in Pareto Securities´ 16^th Annual Healthcare Conference, that takes place on September 16, at Hotel At Six, Brunkebergstorg 6, Stockholm, Sweden.

On the day, between 9:40-10:00 CEST (room Studio 8), Robert Rönn, SVP and Head of R&D, will give a company presentation. Robert Rönn and Lena Wange, Investor Relations Director, will also be available for 1-1 meetings.

For more information contact:

About Orexo
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees to 110. Orexo is listed on Nasdaq Stockholm's main list and is available as ADRs on OTCQX market (ORXOY) in the US.

About AmorphOX®
Orexo’s proprietary drug delivery platform, AmorphOX, is a powder made up of particles that are built using a unique combination of a drug, carrier materials and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure.

For more information about the company please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.